

Overview
Genetics of Ischaemic Stroke
Functional Outcome Study

GISCOME

Arne Lindgren on behalf of
the GISCOME investigators

Background

- Ischemic stroke patients often have considerable functional deficit after stroke

43% mRS 3-6 at discharge

Béjot. Neuroepidemiology 2013;41:169–173

- Some patients recover, some do not recover

Background

- Different mechanisms for recovery
 - “Stunned brain” recovering
 - Repair
 - Plasticity
- Recovery mechanisms may vary by time
 - Early recovery during first days-weeks
 - Later recovery weeks-months-years

Background

Risk for confusion in terminology

Functional outcome: status after ischemic stroke

- E.g. mRS

Recovery: Functional outcome in relation to initial stroke severity

- E.g. mRS in relation to baseline NIHSS

Hypothesis

- Genetic mechanisms influence recovery after cerebral infarct
- An agnostic approach can detect these genetic mechanisms
- These mechanisms can be further studied to better understand recovery after stroke
- This better understanding will lead to treatments enhancing recovery

Primary purpose

Test the hypothesis

genetic variation influences
functional recovery after
the acute phase of ischemic stroke

Other purposes

1. Describe functional outcome and recovery in very large cohort of ischemic stroke patients
2. Recovery in different subgroups
 - Age
 - CCS/TOAST
 - Severity strata
3. Examine genetic influence in the acute phase of ischemic stroke

Methods

- Retrospective study
- Multi-center GWAS
- Primary outcome

Good vs bad Outcome after 3 months

- mRS 0-2 vs 3-6

- adjustment for age, gender, onset NIHSS

Methods

Secondary outcomes:

1. mRS at 3 months as ordinal scale
2. outcome in stroke subtypes
CCS/TOAST
3. 1-year outcome mRS dichotomous
4. mRS evolvment by time

Methods

- Additional Spanish samples n=800
 - Jordi Jimenez Condi
- Meta-analysis/replication with Spanish samples

Retrospective study: compromises necessary

- Baseline time for enrolment
- mRS 3 months
 - Closest to 90 days (60 to 190 days accepted)

Methods

- GISCoME data centrally collected in Cambridge, UK
 - Steve Bevan
 - Phenotypic data
 - Genotype data
- Monthly teleconferences
- Abstracts for conferences
- Description paper
- Phenotypic paper?
- Main paper

Current status Data

- Phenotype data from 14 studies now in Cambridge
- mRS at "90 days" available, n=9412

Cincinnati	Woo	642
Edinburgh	Sudlow/ Rannikmae	625
Helsinki	Tatlisumak/Strbian	469
Hospital del Mar	Jimenes Conde	930
Leuven	Lemmens/Thijs	491
Lund	Lindgren	1161
MGH	Rost/Rosand	1073
Newcastle	Maguire	665
Oxford	Rothwell	553
SAHLISS	Jern	1117
Val de Hebron 1	Fernandez Cadenas	743
Val de Hebron 2	Fernandez Cadenas	610
WASH-U	Lee	256
VISP	Worrall	2100
Total		11453

Baseline characteristics

n in database	11453
Mean (median) age (years)	68.1 (69)
Female (%)	42.2
Hypertension %	67.2
Diabetes %	23.8
Current Smoker	23.8
Atrial fibrillation %	19.6

TOAST / CCS

TOAST	8420
CE	2692
LAA	1499
SVD	1448
Other	508
UND	2273
CCS	5361
CE	1742
LAA	861
SVD	620
Other	270
UND	1868

Baseline NIHSS Outcome mRS

	median	n
Earliest NIHSS, within 1 week	3	10863
time for earliest NIHSS (days)	1	6716
mRS at “90 days”	2	9312

Limitations

- Cohorts enrolled at different time points after stroke onset
- Patients evaluated at different time points after stroke onset
- Mixture of CCS and TOAST
- mRS not available as ordinal scale variable for all sites

Current status Conferences

**GISCOME abstract European Stroke Conference,
Nice, May 2014. Accepted for e-poster presentation**

**Stroke Genetics Symposium at European Stroke Conference
Nice, May 2014. http://www.eurostroke.eu/ni_minisym6.html**

**GISCOME abstract Stroke Society of Australasia meeting
July/August 2014 submitted**

**Proposal of Stroke Genetics Symposium, International Stroke
Conference, Nashville, Feb 2015 submitted**

Current status funding

- Grants received
 - Jern
 - Lindgren
- New applications submitted/planned

Further plans for 2014

- Collect genotype data in Cambridge database
- Write description paper
 - Jane Maguire and writing group
- Analyse early outcome
 - Jin-Moo Lee
- Perform outcome analyses

Thank you

Cincinnati
Edinburgh
Helsinki
Hospital del Mar
Leuven
Lund
MGH
Newcastle
Oxford
SAHLISS
Val de Hebron 1
Val de Hebron 2
WASH-U
VISP

Woo
Sudlow/ Rannikmae
Tatlisumak/Strbian
Jimenes Conde
Lemmens/Thijs
Lindgren
Rost/Rosand
Maguire
Rothwell
Jern
Fernandez Cadenas
Fernandez Cadenas
Lee
Worrall

SiGN
Riksstroke

Steve Bevan